{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T03:06:52Z","timestamp":1792206412805,"version":"4.4.0"},"reference-count":73,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100008373","name":"Takeda Pharmaceutical Co Ltd","doi-asserted-by":"publisher","award":["IIR-BEL-002096"],"award-info":[{"award-number":["IIR-BEL-002096"]}],"id":[{"id":"10.13039\/100008373","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1152518N"],"award-info":[{"award-number":["1152518N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.jtha.2022.12.018","type":"journal-article","created":{"date-parts":[[2023,1,16]],"date-time":"2023-01-16T00:31:23Z","timestamp":1673829083000},"page":"1090-1099","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"title":["Toward gene therapy for congenital thrombotic thrombocytopenic purpura"],"prefix":"10.1016","volume":"21","author":[{"given":"Charlotte","family":"Dekimpe","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elien","family":"Roose","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuya","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Tersteeg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon F.","family":"De Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Vanhoorelbeke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2022.12.018_bib1","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1182\/blood.V98.6.1654","article-title":"Partial amino acid sequence of purified von Willebrand factor\u2013cleaving protease","volume":"98","author":"Gerritsen","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib2","doi-asserted-by":"crossref","first-page":"41059","DOI":"10.1074\/jbc.C100515200","article-title":"Structure of von Willebrand factor-cleaving protease (ADAMTS13), a metalloprotease involved in thrombotic thrombocytopenic purpura","volume":"276","author":"Zheng","year":"2001","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jtha.2022.12.018_bib3","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1038\/35097008","article-title":"Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura","volume":"413","author":"Levy","year":"2001","journal-title":"Nature"},{"key":"10.1016\/j.jtha.2022.12.018_bib4","article-title":"Thrombotic thrombocytopenic purpura","volume":"3","author":"Hovinga","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jtha.2022.12.018_bib5","doi-asserted-by":"crossref","first-page":"2836","DOI":"10.1182\/blood-2016-10-709857","article-title":"Thrombotic thrombocytopenic purpura","volume":"129","author":"Joly","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib6","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1056\/NEJM198212023072306","article-title":"Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura","volume":"307","author":"Moake","year":"1982","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib7","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1182\/blood-2005-01-0152","article-title":"Localization of ADAMTS13 to the stellate cells of human liver","volume":"106","author":"Uemura","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib8","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jth.12221","article-title":"Structure\u2013function and regulation of ADAMTS-13 protease","volume":"11","author":"Zheng","year":"2013","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s12185-009-0476-1","article-title":"Pathophysiology of thrombotic thrombocytopenic purpura","volume":"91","author":"Tsai","year":"2010","journal-title":"Int J Hematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib10","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1586\/17474086.2016.1122515","article-title":"ADAMTS13 and anti-ADAMTS13 autoantibodies in thrombotic thrombocytopenic purpura\u2013current perspectives and new treatment strategies","volume":"9","author":"Tersteeg","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib11","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1182\/blood.V16.1.943.943","article-title":"Studies on thrombopoiesis. I. A factor in normal human plasma required for platelet production; chronic thrombocytopenia due to its deficiency","volume":"16","author":"Schulman","year":"1960","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib12","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1056\/NEJM197806152982407","article-title":"Congenital deficiency of a factor in normal plasma that reverses microangiopathic hemolysis and thrombocytopenia","volume":"298","author":"Upshaw","year":"1978","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib13","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.3324\/haematol.2019.216796","article-title":"The International Hereditary Thrombotic Thrombocytopenic Purpura Registry: key findings at enrollment until 2017","volume":"104","author":"Dorland van","year":"2019","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.12.018_bib14","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1055\/s-0038-1673686","article-title":"ADAMTS13 gene mutations influence adamts13 conformation and disease age-onset in the french cohort of Upshaw-Schulman syndrome","volume":"118","author":"Joly","year":"2018","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib15","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1111\/j.1538-7836.2011.04399.x","article-title":"Polymorphisms and mutations of ADAMTS13 in the Japanese population and estimation of the number of patients with Upshaw\u2013Schulman syndrome","volume":"9","author":"Kokame","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib16","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/humu.21143","article-title":"ADAMTS13 mutations and polymorphisms in congenital thrombotic thrombocytopenic purpura","volume":"31","author":"Lotta","year":"2010","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtha.2022.12.018_bib17","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/ejh.13094","article-title":"Child-onset thrombotic thrombocytopenic purpura caused by p.R498C and p.G259PfsX133 mutations in ADAMTS13","volume":"101","author":"Schelpe","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib18","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1182\/blood-2018-11-884700","article-title":"Characterization and treatment of congenital thrombotic thrombocytopenic purpura","volume":"133","author":"Alwan","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib19","doi-asserted-by":"crossref","first-page":"4749","DOI":"10.1182\/blood-2009-07-230615","article-title":"Mutation of the H-bond acceptor S119 in the ADAMTS13 metalloprotease domain reduces secretion and substrate turnover in a patient with congenital thrombotic thrombocytopenic purpura","volume":"114","author":"Feys","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib20","doi-asserted-by":"crossref","first-page":"e8","DOI":"10.1055\/s-0037-1615252","article-title":"Anti-ADAMTS13 antibodies and a novel Heterozygous p.R1177Q mutation in a case of pregnancy-onset immune-mediated thrombotic thrombocytopenic purpura","volume":"2","author":"Roose","year":"2018","journal-title":"TH Open"},{"key":"10.1016\/j.jtha.2022.12.018_bib21","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1111\/j.1538-7836.2012.04852.x","article-title":"A\u00a0phenotype\u2013genotype correlation of ADAMTS13 mutations in congenital thrombotic thrombocytopenic purpura patients treated in the United Kingdom","volume":"10","author":"Camilleri","year":"2012","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib22","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1111\/j.1538-7836.2008.02846.x","article-title":"Prevalence of the ADAMTS-13 missense mutation R1060W in late onset adult thrombotic thrombocytopenic purpura","volume":"6","author":"Camilleri","year":"2008","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib23","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1002\/humu.20267","article-title":"Mechanisms of the interaction between two ADAMTS13 gene mutations leading to severe deficiency of enzymatic activity","volume":"27","author":"Peyvandi","year":"2006","journal-title":"Hum Mutat"},{"key":"10.1016\/j.jtha.2022.12.018_bib24","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13107","article-title":"Pediatric thrombotic thrombocytopenic purpura","volume":"101","author":"Joly","year":"2018","journal-title":"Eur J Haematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib25","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1111\/jth.15006","article-title":"ISTH guidelines for the diagnosis of thrombotic thrombocytopenic purpura","volume":"18","author":"Zheng","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib26","doi-asserted-by":"crossref","first-page":"2929","DOI":"10.1111\/jth.15064","article-title":"Success and limitations of plasma treatment in pregnant women with congenital thrombotic thrombocytopenic purpura","volume":"18","author":"Sakai","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib27","doi-asserted-by":"crossref","first-page":"5888","DOI":"10.1182\/blood-2012-02-408914","article-title":"Unexpected frequency of Upshaw-Schulman syndrome in pregnancy-onset thrombotic thrombocytopenic purpura","volume":"119","author":"Moatti-Cohen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib28","doi-asserted-by":"crossref","first-page":"3191","DOI":"10.1182\/bloodadvances.2019000601","article-title":"Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome","volume":"3","author":"Fujimura","year":"2019","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2022.12.018_bib29","doi-asserted-by":"crossref","first-page":"1653","DOI":"10.1056\/NEJMra1813013","article-title":"Hereditary thrombotic thrombocytopenic purpura","volume":"381","author":"Kremer Hovinga","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib30","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1111\/bjh.17560","article-title":"Current prophylactic plasma infusion protocols do not adequately prevent long-term cumulative organ damage in the Japanese congenital thrombotic thrombocytopenic purpura cohort","volume":"194","author":"Sakai","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib31","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1111\/jth.14345","article-title":"Pharmacokinetics of plasma infusion in congenital thrombotic thrombocytopenic purpura","volume":"17","author":"Taylor","year":"2019","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1055\/s-0037-1614408","article-title":"Recovery and half-life of von Willebrand factor-cleaving protease after plasma therapy in patients with thrombotic thrombocytopenic purpura","volume":"81","author":"Furlan","year":"1999","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1046\/j.1365-2141.2001.03222.x","article-title":"Plasma of patients with Upshaw\u2013Schulman syndrome, a congenital deficiency of von Willebrand factor-cleaving protease activity, enhances the aggregation of normal platelets under high shear stress","volume":"115","author":"Yagi","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib34","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1002\/rth2.12160","article-title":"Thrombotic thrombocytopenic purpura: Toward targeted therapy and precision medicine","volume":"3","author":"Coppo","year":"2019","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib35","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/blood-2017-06-788026","article-title":"Recombinant ADAMTS-13: first-in-human pharmacokinetics and safety in congenital thrombotic thrombocytopenic purpura","volume":"130","author":"Scully","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib36","doi-asserted-by":"crossref","first-page":"E22","DOI":"10.1002\/ajh.23851","article-title":"Development of a clinically significant ADAMTS13 inhibitor in a patient with hereditary thrombotic thrombocytopenic purpura","volume":"90","author":"Raval","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib37","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1538-7836.2011.04341.x","article-title":"Natural history of Upshaw\u2013Schulman syndrome based on ADAMTS13 gene analysis in Japan","volume":"9","author":"Fujimura","year":"2011","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib38","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1002\/ajh.24060","article-title":"Depression and cognitive impairment following recovery from thrombotic thrombocytopenic purpura","volume":"90","author":"Han","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib39","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1182\/blood-2013-04-496752","article-title":"Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura","volume":"122","author":"Deford","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib40","first-page":"365","article-title":"Influence of personality, resilience and life conditions on depression and anxiety in 104 patients having survived acute autoimmune thrombotic thrombocytopenic purpura","volume":"10","author":"Falter","year":"2021","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib41","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.3324\/haematol.2019.226423","article-title":"Long-term neuropsychological sequelae, emotional wellbeing and quality of life in patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Riva","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.12.018_bib42","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221112217","article-title":"Management of acquired, immune thrombocytopenic purpura (iTTP): beyond the acute phase","volume":"13","author":"Westwood","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.jtha.2022.12.018_bib43","doi-asserted-by":"crossref","first-page":"3825","DOI":"10.1182\/blood-2013-02-486779","article-title":"AAV-mediated expression of an ADAMTS13 variant prevents shigatoxin-induced thrombotic thrombocytopenic purpura","volume":"121","author":"Jin","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib44","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1161\/ATVBAHA.116.308680","article-title":"Long-term prevention of congenital thrombotic thrombocytopenic purpura in adamts13 knockout mice by sleeping beauty transposon-mediated gene therapy","volume":"37","author":"Verhenne","year":"2018","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jtha.2022.12.018_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/mt.2008.223","article-title":"Correction of ADAMTS13 deficiency by in utero gene transfer of lentiviral vector encoding ADAMTS13 genes","volume":"17","author":"Niiya","year":"2009","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.018_bib46","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1182\/blood-2008-08-173021","article-title":"Correction of murine ADAMTS13 deficiency by hematopoietic progenitor cell\u2013mediated gene therapy","volume":"113","author":"Laje","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib47","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1038\/gt.2009.98","article-title":"Adenoviral-mediated gene transfer restores plasma ADAMTS13 antigen and activity in ADAMTS13 knockout mice","volume":"16","author":"Trionfini","year":"2009","journal-title":"Gene Ther"},{"key":"10.1016\/j.jtha.2022.12.018_bib48","doi-asserted-by":"crossref","first-page":"7859","DOI":"10.1038\/s41598-018-26298-4","article-title":"mRNA treatment produces sustained expression of enzymatically active human ADAMTS13 in mice","volume":"8","author":"Liu-Chen","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.jtha.2022.12.018_bib49","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1182\/blood-2011-12-399501","article-title":"Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura","volume":"119","author":"Jian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib50","doi-asserted-by":"crossref","first-page":"18578","DOI":"10.1073\/pnas.1411979112","article-title":"Conformational activation of ADAMTS13","volume":"111","author":"South","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtha.2022.12.018_bib51","doi-asserted-by":"crossref","first-page":"18584","DOI":"10.1073\/pnas.1413282112","article-title":"Allosteric activation of ADAMTS13 by von Willebrand factor","volume":"111","author":"Muia","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.jtha.2022.12.018_bib52","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.3324\/haematol.2019.226068","article-title":"Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura","volume":"105","author":"Gra\u00e7a","year":"2020","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2022.12.018_bib53","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810228","article-title":"The arrival of gene therapy for patients with hemophilia A","volume":"23","author":"Castaman","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtha.2022.12.018_bib54","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/hae.14545","article-title":"Gene therapy: practical aspects of implementation","volume":"28","author":"Pipe","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2022.12.018_bib55","article-title":"Adeno-associated virus gene therapy for hemophilia","author":"Samelson-Jones","year":"2022","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib56","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1038\/mt.2010.169","article-title":"Hyperactive sleeping\u00a0beauty transposase enables persistent phenotypic correction in mice and a canine model for hemophilia B","volume":"18","author":"Hausl","year":"2010","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.018_bib57","doi-asserted-by":"crossref","first-page":"3563","DOI":"10.1182\/blood.2020009801","article-title":"Annual incidence and severity of acute episodes in hereditary thrombotic thrombocytopenic purpura","volume":"137","author":"Tarasco","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2022.12.018_bib58","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.omtm.2019.01.010","article-title":"EU regulatory pathways for ATMPs: standard, accelerated and adaptive pathways to marketing authorisation","volume":"13","author":"Detela","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2022.12.018_bib59","article-title":"Gene therapies development: slow progress and promising prospect","volume":"5","author":"Hanna","year":"2017","journal-title":"J\u00a0Mark Access Health Policy"},{"key":"10.1016\/j.jtha.2022.12.018_bib60","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.jcyt.2020.11.008","article-title":"Comparison of regulatory pathways for the approval of advanced therapies in the European Union and the United States","volume":"23","author":"Iglesias-Lopez","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtha.2022.12.018_bib61","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1016\/j.jcyt.2018.03.038","article-title":"A\u00a0decade of marketing approval of gene and cell-based therapies in the United States, European Union and Japan: an evaluation of regulatory decision-making","volume":"20","author":"Coppens","year":"2018","journal-title":"Cytotherapy"},{"key":"10.1016\/j.jtha.2022.12.018_bib62","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol Genet Metab"},{"key":"10.1016\/j.jtha.2022.12.018_bib63","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1056\/NEJM200301163480314","article-title":"A\u00a0serious adverse event after successful gene therapy for x-linked severe combined immunodeficiency","volume":"348","author":"Hacein-Bey-Abina","year":"2003","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib64","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1002\/jgm.619","article-title":"Gene therapy clinical trials worldwide 1989\u20132004\u2014an overview","volume":"6","author":"Edelstein","year":"2004","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib65","doi-asserted-by":"crossref","DOI":"10.1038\/mtm.2016.73","article-title":"Clinical development of gene- and cell-based therapies: overview of the European landscape","volume":"3","author":"de Wilde","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"10.1016\/j.jtha.2022.12.018_bib66","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3015","article-title":"Gene therapy clinical trials worldwide to 2017: an update","volume":"20","author":"Ginn","year":"2018","journal-title":"J\u00a0Gene Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib67","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/jth.13938","article-title":"High and long-term von Willebrand factor expression after Sleeping Beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease","volume":"16","author":"Portier","year":"2018","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2022.12.018_bib68","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1038\/mt.2016.11","article-title":"Genome-wide profiling reveals remarkable parallels between insertion site selection properties of the mlv retrovirus and the piggybac transposon in primary human CD4+ T cells","volume":"24","author":"Gogol-D\u00f6ring","year":"2016","journal-title":"Mol Ther"},{"key":"10.1016\/j.jtha.2022.12.018_bib69","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/s41591-019-0676-z","article-title":"Benefit corporation: a path to affordable gene therapies?","volume":"25","author":"Fischer","year":"2019","journal-title":"Nat Med"},{"issue":"22","key":"10.1016\/j.jtha.2022.12.018_bib70","first-page":"02100","article-title":"Challenges for economic evaluations of advanced therapy medicinal products: a systematic review","volume":"S1098-3015","author":"de Labry-Lima","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jtha.2022.12.018_bib71","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s40290-022-00443-x","article-title":"Pricing and market access challenges in the era of one-time administration cell and gene therapies","volume":"36","author":"Sabatini","year":"2022","journal-title":"Pharm Med"},{"key":"10.1016\/j.jtha.2022.12.018_bib72","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1126\/science.aaf4770","article-title":"MEDICINE. Paying for future success in gene therapy","volume":"352","author":"Orkin","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.jtha.2022.12.018_bib73","first-page":"559","article-title":"Gene therapy and hemophilia: where do we go from here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J\u00a0Blood Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622182905?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783622182905?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T03:38:10Z","timestamp":1761536290000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783622182905"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":73,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S1538783622182905"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.018","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Toward gene therapy for congenital thrombotic thrombocytopenic purpura","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2022.12.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society on Thrombosis and Haemostasis. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}